RealFeedApp Intismeran reduces melanoma recurrence risk by half
Intismeran Autogene combined with existing immunotherapy significantly reduced melanoma recurrence risk and mortality. Results were confirmed at the 2026 European Society for Medical Oncology Congress in Madrid.
- Field
- cancer research
- What they did
- Researchers demonstrated in a Phase 3 clinical trial that a new personalized treatment, combining existing immunotherapy with individual genetic customization, significantly reduced the risk of melanoma recurrence and death.
- Why it matters
- These findings bring a new class of personalized cancer medicine closer to reality by using the patient's immune system to target their unique tumors.
#melanoma#immunotherapy#clinical trial#personalized medicine#moderna#merck
